Royal Lifescience Corp. Announces Filing of Amended and Restated Financial Statements for the Quarter
ROYAL LIFESCIENCE CORP.
1780 – 400 Burrard Street
Vancouver, British Columbia V6B 3K1
NEWS RELEASE
Royal Lifescience Corp. Announces Filing of Amended and Restated Financial Statements for the Quarter
Ended December 31, 2017
April 19, 2018 NEX Board of the TSX Venture Exchange
Trading Symbol: RLS.H
Vancouver, BC – Royal Lifescience Corp. (NEX: “RLS.H”) (the “Company”), a capital pool company
pursuant to Policy 2.4 of the TSX Venture Exchange (the “Exchange”), announces filing of its amended
and restated financial statements (together with an amended corresponding management’s discuss ion and
analysis) for the quarter ended December 31, 2017 (collectively, the “Amended Financial Report”) to
correct the accounting errors identified below.
Financial Statements
The financial statements have been restated to: (i) increase the Company's accounts payable and accruals
by $17,144, and to (ii) decrease GST receivables by $421 with a corresponding increase to the net loss for
the period of $17,565. The net loss was increased due to increases in accounting and legal fees of $14,110,
legal fees of $192 and stock transfer agent and filing fees of $3,263 . The net loss for the three month
period ended December 31, 2016 was restated to derecognize GST receivables of $325, with a
corresponding increase in net loss for the period.
Management's Discussion and Analysis
Management’s discussions and analysis were revised to be consistent with the updates to the financial
statements as noted above.
The Amended Financial Report is available under the Company’s profile on SEDAR at www.sedar.com.
On behalf of the Board of Directors
Minaz Dhanani
Chief Executive Officer, Chief Financial Officer, Director
For further information please contact:
Minaz Dhanani
Telephone: (604) 783-7361
Neither the TSX Venture Exchange not its Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.